Compare F5 Inc (FFIV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Zimmer Biomet Holdings Inc — how do they compare? F5 Inc trades at $418.22 (market cap $23.44B), while Zimmer Biomet Holdings Inc trades at $95.97 (market cap $18.55B). The key difference: F5 Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| FFIV | ZBH | |
|---|---|---|
Market Cap | $23.44B | $18.55B |
Sector | Technology | Health |
52-Week High | $431.26 | $107.71 |
52-Week Low | $223.99 | $79.58 |
Enterprise Value | $22.08B | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $414.00, up 0.98% in the last session, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.09 billion in 2025, with a net income margin of 21.95%, while the company raised its annual revenue forecast on robust cybersecurity demand (Reuters, 2026-07-27). The stock is near resistance at $417, with RSI indicating mild overbought conditions.
The outlook remains positive due to consistent earnings outperformance and AI-driven security growth, but risks include high valuation multiples (P/E of 32.98) and competitive pressures. Analysts maintain a moderate buy consensus with a $430.43 price target, suggesting potential upside from current levels.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
